DenialHelpUnderstand your spinal muscular atrophy denial. Build a reviewable appeal.
Upload the denial notice, verify the extracted facts, identify missing evidence, and prepare a package for treating-clinician review. The notice and applicable rules determine the available route and deadline.
Start my appeal→
See how it worksThe denial notice
Confirm the payer's stated reason, plan language, dates, and review rights from the actual notice.
Facts and evidence
Keep extracted information linked to its source. Unknown facts stay unknown until you or the clinician confirms them.
Route and review
Classify the next step, verify any deadline, and identify what requires treating-clinician review or signature.
Four clear stages.
Upload your denial — and any clinical records you have
Take a photo, scan, or upload PDFs of the denial letter. Adding labs, prior PA letters, or visit notes makes the appeal stronger — but the denial alone is enough to start.
Confirm a few facts
We pre-fill what was extracted. You confirm, correct, or leave it unknown.
We draft your appeal
A source-linked draft and evidence checklist for treating-clinician review.
Your doctor signs and files
We email the letter to you. Your doctor reviews, signs, and submits.
Common questions
Can I appeal a denied insurance claim for Spinal muscular atrophy?
The denial notice and governing plan or program determine whether and how the decision can be challenged. DenialHelp first classifies the route, then organizes the relevant facts and sources. Filing dates vary and must be verified against the actual notice.
What does DenialHelp cost for a Spinal muscular atrophy appeal?
$39 for a first-level appeal. Other review levels use the current prices shown on the pricing page. The refund promise concerns the described deliverable, not the insurer's decision.
Who reviews and signs the Spinal muscular atrophy appeal letter?
The patient's treating physician reviews and signs the appeal letter before it is submitted to the insurer. DenialHelp drafts the letter; the patient and prescribing physician are responsible for submission. We do not file appeals on behalf of patients.
What treatments are covered under Spinal muscular atrophy?
Spinraza (nusinersen) — antisense oligonucleotide intrathecal, 12 mg loading (days 0/14/28/63) then maintenance q4mo, FDA Dec 23, 2016 ALL SMA types ages 0-99, Evrysdi (risdiplam) — oral SMN2 splicing modifier daily, FDA Aug 7, 2020 (>=2 mo) → expanded May 30, 2022 to neonates >=2 wk; tablet form approved 2024 for >=2 yr and >=20 kg, Zolgensma (onasemnogene abeparvovec-xioi) — single-dose IV AAV9 gene therapy 1.1×10^14 vg/kg, FDA May 24, 2019 pediatric SMA <2 yr with bi-allelic SMN1 mutations (combination kits required >=13.6 kg), Combination / sequential therapy — Zolgensma followed by Spinraza or Evrysdi maintenance (RESTORE registry + multiple case series; selected post-Zolgensma plateau or slow responders), Switching therapy — Spinraza→Evrysdi (oral preference, scoliosis fixation hardware, intrathecal access failure) or Evrysdi→Spinraza (JEWELFISH switcher cohort), Non-invasive ventilation (BiPAP) — nocturnal then daytime as FVC <60% predicted; SMA Standards of Care 2018 Part 2 respiratory consensus, Tracheostomy + invasive ventilation — Type 1 with respiratory failure, family-elected after shared decision-making per SMA SoC 2018 Part 2 ethics, Gastrostomy tube (PEG / G-tube) — bulbar dysfunction, failure to thrive, swallowing safety per SoC 2018 Part 1 nutrition
Ready to fight your denial?
Our free pre-payment review runs before checkout. Refund requests made within 7 calendar days of payment are processed automatically; later requests are reviewed under the Terms. A refund policy is not a promise of a payer outcome.
Start my appeal→